Biocytogen Biotechnology
Latest round
- Series E
Last raised
- Jun 2021
Total raised
- $291M
Investors
- 12
About Biocytogen Biotechnology
Founded in 2008 and based in Beijing, China, Biocytogen Biotechnology is a biotechnology company that engages in the research and development innovative antibody drugs for oncology, autoimmune, metabolic and anti-infection-related diseases. The company's founder and CEO, Shen Yuelei, received a PhD in Immunology from the University of Massachusetts School of Medicine. He has nearly 30 years of experience in immunology, gene editing, model animal disease model development, and antibody drug development. The drugs developed by the company include monoclonal antibodies, bispecific antibodies, ADC drugs, etc. In addition, relying on the self-developed fully human antibodies RenMab, RenLite and other mouse platforms, through the integration of mouse target gene knockout technology, high-throughput single B cell antibody discovery technology, and rapid animal efficacy evaluation in vivo platform, the company has developed a large-scale research and development plan for innovative target antibodies. Through this plan, the company will conduct antibody discovery and in vivo drug efficacy screening on potential antibody drug targets, focusing on the discovery of drug targets and lead antibody molecules with first-in-class and best-in-class potential. The company generates revenue from developing innovative antibody drugs for oncology, autoimmune, metabolic and anti-infection-related diseases.68 per share on the STAR Market.
Who invested in Biocytogen Biotechnology
12 investors across 6 rounds
See all investors in Biocytogen Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Biocytogen Biotechnology
Who invested in Biocytogen Biotechnology?
Biocytogen Biotechnology has 12 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Biocytogen Biotechnology raised?
Biocytogen Biotechnology has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Biocytogen Biotechnology last raise money?
Biocytogen Biotechnology's most recent round on record is a Series E, in Jun 2021.
What does Biocytogen Biotechnology do?
Founded in 2008 and based in Beijing, China, Biocytogen Biotechnology is a biotechnology company that engages in the research and development innovative antibody drugs for oncology, autoimmune, metabolic and anti-infection-related diseases.
Where is Biocytogen Biotechnology headquartered?
Biocytogen Biotechnology is headquartered in Beijing, China.
Which VCs invest in companies like Biocytogen Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Biocytogen Biotechnology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like Biocytogen Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.